Abstract
Page 12198. Instead of The authors declare no competing financial interest , the following Note should be included: The authors declare the following competing financial interest(s): Y.K. is a founder and equity holder of Firebrand Therapeutics, Inc, which is developing inhibitors against MTDH/SND1. Received.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 7668 |
| Number of pages | 1 |
| Journal | Journal of Medicinal Chemistry |
| Volume | 66 |
| Issue number | 11 |
| DOIs |
|
| State | Published - Jun 8 2023 |
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Drug Discovery
Fingerprint
Dive into the research topics of 'Correction: Structure-based design, optimization, and evaluation of potent stabilized peptide inhibitors disrupting MTDH and SND1 interaction (Journal of Medicinal Chemistry (2022) 65:18 (12188-12199) DOI: 10.1021/acs.jmedchem.2c00862)'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver